BR112020022829A2 - inibidores do receptor erbb - Google Patents
inibidores do receptor erbb Download PDFInfo
- Publication number
- BR112020022829A2 BR112020022829A2 BR112020022829-0A BR112020022829A BR112020022829A2 BR 112020022829 A2 BR112020022829 A2 BR 112020022829A2 BR 112020022829 A BR112020022829 A BR 112020022829A BR 112020022829 A2 BR112020022829 A2 BR 112020022829A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- halogen
- hydroxyl
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/085998 | 2018-05-08 | ||
| CN2018085998 | 2018-05-08 | ||
| PCT/CN2019/085949 WO2019214634A1 (en) | 2018-05-08 | 2019-05-08 | Erbb receptor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020022829A2 true BR112020022829A2 (pt) | 2021-02-02 |
Family
ID=68467752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020022829-0A BR112020022829A2 (pt) | 2018-05-08 | 2019-05-08 | inibidores do receptor erbb |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10822334B2 (https=) |
| EP (2) | EP4410291A3 (https=) |
| JP (2) | JP7540953B2 (https=) |
| KR (1) | KR102806778B1 (https=) |
| CN (4) | CN112266384B (https=) |
| AR (1) | AR117424A1 (https=) |
| AU (1) | AU2019267959B2 (https=) |
| BR (1) | BR112020022829A2 (https=) |
| CA (1) | CA3099315A1 (https=) |
| DK (1) | DK3814341T3 (https=) |
| ES (1) | ES2977196T3 (https=) |
| MX (2) | MX2020011868A (https=) |
| PT (1) | PT3814341T (https=) |
| TW (2) | TWI858848B (https=) |
| WO (1) | WO2019214634A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| TWI858848B (zh) * | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| TWI879751B (zh) * | 2020-03-23 | 2025-04-11 | 印度商皮埃企業有限公司 | 3-被取代的苯基脒化合物及其製備和用途 |
| CA3194724A1 (en) * | 2020-10-05 | 2022-04-14 | Dana-Farber Cancer Institute, Inc. | Potent and selective inhibitors of her2 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| IL312004A (en) * | 2021-10-20 | 2024-06-01 | Hoffmann La Roche | Crystalline forms of quinazoline derivatives, their preparation, assembly and use |
| CN114262327B (zh) * | 2021-12-30 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
| CN114671867B (zh) * | 2022-03-15 | 2023-09-19 | 上海法默生物科技有限公司 | 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法 |
| CN118715216A (zh) * | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023410324A1 (en) | 2022-12-22 | 2025-05-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| CN116102491A (zh) * | 2023-02-17 | 2023-05-12 | 浙江晖石药业有限公司 | 一种利用连续流技术进行金属催化偶联的应用 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121568696A (zh) | 2023-07-28 | 2026-02-24 | 勃林格殷格翰国际有限公司 | 制备her2抑制剂的方法 |
| WO2025051148A1 (zh) * | 2023-09-05 | 2025-03-13 | 北京鞍石生物科技股份有限公司 | 含氮杂芳基化合物及其制备方法和应用 |
| CN117534669A (zh) * | 2023-11-01 | 2024-02-09 | 上海凌凯医药科技有限公司 | 五元氮杂环并吡啶醇的制备方法 |
| CN117658818B (zh) * | 2023-11-03 | 2025-02-07 | 江西巍华化学有限公司 | 一种4-氟-3-硝基三氟甲苯的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US20050043336A1 (en) * | 2001-11-03 | 2005-02-24 | Hennequin Laurent Francois Andre | Quinazoline derivatives as antitumor agents |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物 |
| ATE488513T1 (de) * | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| TWI858848B (zh) | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
-
2019
- 2019-05-07 TW TW112129260A patent/TWI858848B/zh active
- 2019-05-07 TW TW108115721A patent/TWI811358B/zh active
- 2019-05-07 AR ARP190101206A patent/AR117424A1/es unknown
- 2019-05-08 AU AU2019267959A patent/AU2019267959B2/en active Active
- 2019-05-08 KR KR1020207034917A patent/KR102806778B1/ko active Active
- 2019-05-08 JP JP2020562751A patent/JP7540953B2/ja active Active
- 2019-05-08 CN CN202010657663.6A patent/CN112266384B/zh active Active
- 2019-05-08 MX MX2020011868A patent/MX2020011868A/es unknown
- 2019-05-08 WO PCT/CN2019/085949 patent/WO2019214634A1/en not_active Ceased
- 2019-05-08 CA CA3099315A patent/CA3099315A1/en active Pending
- 2019-05-08 EP EP24164213.1A patent/EP4410291A3/en active Pending
- 2019-05-08 CN CN202010656946.9A patent/CN111747953B/zh active Active
- 2019-05-08 CN CN202010657654.7A patent/CN111662289A/zh active Pending
- 2019-05-08 DK DK19800509.2T patent/DK3814341T3/da active
- 2019-05-08 PT PT198005092T patent/PT3814341T/pt unknown
- 2019-05-08 ES ES19800509T patent/ES2977196T3/es active Active
- 2019-05-08 EP EP19800509.2A patent/EP3814341B1/en active Active
- 2019-05-08 BR BR112020022829-0A patent/BR112020022829A2/pt active Search and Examination
- 2019-05-08 CN CN201980006431.XA patent/CN111587248A/zh active Pending
-
2020
- 2020-06-24 US US16/910,267 patent/US10822334B2/en active Active
- 2020-09-23 US US17/029,074 patent/US11447492B2/en active Active
- 2020-11-06 MX MX2023008954A patent/MX2023008954A/es unknown
-
2024
- 2024-01-22 JP JP2024007265A patent/JP7810734B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020022829A2 (pt) | inibidores do receptor erbb | |
| WO2017092413A1 (zh) | 一种二氨基嘧啶化合物及包含该化合物的组合物 | |
| CN102482277A (zh) | 表皮生长因子受体抑制剂及治疗障碍的方法 | |
| BR112016003247B1 (pt) | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso | |
| BR122021004509B1 (pt) | Sais de inibidor de pi3k e processos para seu preparo | |
| BRPI0710293A2 (pt) | n-(aril- ou heteroaril)-pirazol[1,5-a]pirimidinas 3-substituìdas como inibidores de cinase | |
| ES3061587T3 (en) | Azaheteroaryl compound, preparation method therefor, and application thereof | |
| US20220411422A1 (en) | Erbb receptor inhibitors | |
| RU2810215C2 (ru) | Ингибиторы рецепторов erbb | |
| RU2672725C2 (ru) | Способ получения соединения | |
| HK40114639A (en) | Erbb receptor inhibitors | |
| US20240140947A1 (en) | Compound for the treatment of cancer | |
| HK40045061B (en) | Erbb receptor inhibitors | |
| HK40046084B (en) | Erbb receptor inhibitors | |
| HK40046084A (en) | Erbb receptor inhibitors | |
| HK40037928B (en) | Erbb receptor inhibitors | |
| HK40037928A (en) | Erbb receptor inhibitors | |
| HK40045061A (en) | Erbb receptor inhibitors | |
| HK40028318A (en) | Erbb receptor inhibitors | |
| HK40028142A (en) | Erbb receptor inhibitors | |
| RU2635359C2 (ru) | Промежуточные химические соединения и способы получения соединений | |
| BR112017018312B1 (pt) | Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |